Yi Lin, MD, PhD


Dr. Lin on Patient Eligibility for CAR T-cell Therapy in Hematologic Caners

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.

Mount Sinai


Mount Sinai Researchers Report Encouraging Immunotherapy Option for Relapsed Myeloma

T-cell redirection therapy has shown to be effective in patients unresponsive to initial bispecific antibody treatment.

Yazan Madanat, MD, UT Southwestern Medical Center


Future Directions in MDS

Yazan Madanat, MD, and Mikkael A. Sekeres, MD, discuss future directions and novel therapeutic agents for patients with MDS.

Jose Maria Mazarico Gallego, MD


Dr. Gallego on the Impact of COVID-19 on Cancer Care in Spain

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Neil Vasan, MD, PhD


Dr. Vasan on Advancing the Treatment of Small HER2+ Breast Cancer

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Ignace B. Vergote, MD, PhD


Dr. Vergote on the Need to Develop Novel Therapies in Endometrial Cancer

Ignace B. Vergote, MD, PhD, discusses the need to develop novel therapies in endometrial cancer.

Erin Roesch, MD


A Dynamic Treatment Landscape Emerges for Early-Stage TNBC

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

John Nakayama, MD


Immunotherapy and You: Checkpoint Inhibitors in Gynecologic Cancers

In this sixth episode of OncChats: Immunotherapy and You, John Nakayama, MD, and Ali Amjad, MD, highlight the success seen with checkpoint inhibitors in gynecologic cancers, biomarkers of interest, and recent approvals in the space.

Alison Schram, MD


Dr. Schram on the Efficacy of RLY-4008 in FGFR2+ Cholangiocarcinoma

Alison Schram, MD, discusses the efficacy and safety of RLY-4008 in patients with cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.

Patrick Boland, MD


Dr. Boland on Leveraging Triplet Chemo Regimens in Non-Resectable Liver-Only mCRC

Patrick Boland, MD, discusses therapeutic options for patients with patients with liver-only metastatic colorectal cancer.

Upal Basu Roy, PhD, MPH


Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Thomas Cluzeau, MD, PhD


Dr. Cluzeau on the Efficacy of APR-246/Azacitidine in TP53-Mutated MDS and AML

Thomas Cluzeau, MD, PhD, discusses the response rates of a phase 2 study with APR-246 and azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia.

Anne P. O’Dea, MD


Optimizing Management of HR+/HER2- BC: Future Directions in Care

Closing out their discussion on HR+, HER2- breast cancer, expert panelists share their excitement for further evolution in the treatment paradigm.

Allen Mo, MD, PhD


28-Gene Score May Predict Distant Metastatic Recurrence in Advanced Head and Neck Cancers

Although the ability to treat head and neck cancer has certainly improved over the years, a significant percentage of patients experience recurrent disease after initial treatment.

Henry S. Park, MD, MPH


Creating the In-Person Experience on a Virtual Platform

The coronavirus disease 2019 crisis has changed all aspects of medical education but perhaps altered clinical education most dramatically.

Adam M. Brufsky, MD, PhD, University of Pittsburgh/UPMC Hillman Cancer Center


Dr. Brufsky on the Efficacy of Enobosarm in ER+/AR+ Breast Cancer

Adam M. Brufsky, MD, PhD, FACP, discusses efficacy data with enobosarm in metastatic estrogen receptor–positive, androgen receptor–positive, HER2-negative breast cancer.

David O’Malley, MD


Sequencing Therapy for MSI-High and MMR-Proficient Endometrial Carcinomas

A discussion on the best way to sequence therapies for patients with MSI-high and MMR-proficient endometrial carcinoma.

Larry Hanover


Clinical Trial Diversity Efforts Gain Steam

Nearly 30 years after National Institutes of Health sought to increase participation of minorities in clinical trials, a demographic imbalance remains.